StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3037% below fair value
$18.41+0.00 (0.00%)

Close on Nov 20, 2026Market cap $1.33BP/E 9.3Yield –

Innoviva gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Innoviva's gross profit for the twelve months ending Sep 30, 2026 was $326.50M, up 5.3% year over year. For fiscal 2025 it was $307.67M, up 3.9% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$307.67M+3.9%
FY2024Dec 31, 2024$296.21M+20.4%
FY2023Dec 31, 2023$246.04M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$84.38M+11.7%
Q2 FY2026Jun 30, 2026$90.62M+9.0%
Q1 FY2026Mar 31, 2026$75.83M+3.4%
Q4 FY2025Dec 31, 2025$75.67M-3.2%
Q3 FY2025Sep 30, 2025$75.54M+3.5%
Q2 FY2025Jun 30, 2025$83.15M-2.2%
Q1 FY2025Mar 31, 2025$73.32M+22.0%
Q4 FY2024Dec 31, 2024$78.13M–
Q3 FY2024Sep 30, 2024$73.01M–
Q2 FY2024Jun 30, 2024$84.99M–
Q1 FY2024Mar 31, 2024$60.09M–

More Innoviva figures

See a number that looks wrong?